Yes, the most clinically effective immunotherapy programs for cancer are focused helping NK cells. For example, Riuximab™ and Herceptin™ are currently the world’s largest selling immunotherapy drugs and both are monoclonal antibodies targeting tumor antigens. “ (i.e., THE WORD BOTH APPEARS TWICE). These therapeutic anti-cancer antibodies do not kill cancer cells on their own, they require NK cells to bind the fragment crystallizable (FC) portion of the antibody for effective cancer killing. Put another way, INKmune™ helps NK cells target and kill the tumor cell using a different method than these anti-cancer monoclonal antibodies, but with the same results. Unlike Riuximab™ and Herceptin™, INKmune is not antigen-specific so there is no need to identify the specific tumor antigen.